Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces that the French version of its 2024 Universal Registration Document was filed with the French Financial Markets Authority (Autorité des marchés financiers – AMF) on April 10, 2025, under number D.25-0243.
This document, available on the AMF’s website (www.amf-france.org), can be viewed and downloaded (in PDF format in French and English, and in ESEF format in French only) on Transgene’s website (www.transgene.fr)
It includes the following documents:
- the Annual Financial Report;
- the Board of Directors’ Corporate Governance Report;
- the Statutory Auditors’ Reports;
- information on the Company’s share capital, including the share buyback program;
- information on the Statutory Auditors’ fees.
The Universal Registration Document also includes information on the Company’s Environmental, Social and Governance (ESG) factors.
Attachment
- 20250410_Transgene_publication_URD_2024_EN
GlobeNewswire,is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Latest posts by GlobeNewswire (see all)
- ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Krispy Kreme, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – DNUT - May 24, 2025
- ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Iovance Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – IOVA - May 24, 2025
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TASK, RDFN, DNB on Behalf of Shareholders - May 24, 2025
